Showing 1 - 10 of 13
"Efforts to strengthen the global patent system for pharmaceuticals continue to be controversial, and what will likely be a similarly fraught international debate over price controls has begun. The outcome of international negotiations and the resulting policy decisions made by each country will...
Persistent link: https://www.econbiz.de/10002822126
Persistent link: https://www.econbiz.de/10001808638
Persistent link: https://www.econbiz.de/10001673856
Persistent link: https://www.econbiz.de/10001637684
Persistent link: https://www.econbiz.de/10001550163
Persistent link: https://www.econbiz.de/10001448427
Persistent link: https://www.econbiz.de/10000913202
A public economics framework is used to consider how pharmaceuticals should be priced when at least some of the research and development incentive comes from sales revenues. Familiar techniques of public finance are used to relax some of the restrictions implied in the standard use of Ramsey...
Persistent link: https://www.econbiz.de/10012564071
Since the late 1980s the global intellectual property rights (IPR) system has been strengthening dramatically as much of the developing world introduces patent protection for new drug products. This may lead to more research on drugs to address developing country needs. As there are identifiable...
Persistent link: https://www.econbiz.de/10012471281
We use a public economics framework to consider how pharmaceuticals should be priced when at least some of the Ramp;D incentive comes from sales revenues. We employ familiar techniques of public finance to relax some of the restrictions implied in the standard use of Ramsey pricing. In the more...
Persistent link: https://www.econbiz.de/10012709023